NCT06561724

Brief Summary

The study described herein seeks to assess the extent to which diet supplementation of young Egyptian children, one of the most vulnerable groups to the risk of diarrhea, with prebiotic fiber can improve their gut health.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jun 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

April 9, 2024

Completed
4 months until next milestone

First Posted

Study publicly available on registry

August 20, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2025

Completed
Last Updated

August 20, 2024

Status Verified

February 1, 2024

Enrollment Period

1.7 years

First QC Date

April 9, 2024

Last Update Submit

August 15, 2024

Conditions

Keywords

Gut microbiomeDiarrheaIrritable bowel syndromeInulin prebioticMetagenomic analysisFecal Secretory immunoglobulin AFecal short chain fatty acids

Outcome Measures

Primary Outcomes (1)

  • Fecal secretory immune globulin A (sIgA)

    Fecal secretory s-IGA was assayed by the Chrom ELISA kit (Bio Vender research Diagnostics, Cat # RIC6100, Germany) and the instruction of the manufacturer was followed. Aliquots (80-120 mg) of the thawed fecal samples collected above at baseline and at the termination of the trial were suspended in 10-fold exes (15 m) shitoog a phspaste burier protered and entrifuged at 3o0 omn for s min. Tipes were simultaneously run in the ELISA and the concentration of s-IgA was read at 405 mm in ELISA reader against a standard curve and the results were expressed as mg faecal S-IgA per 100 gram stool.

    2 months

Secondary Outcomes (2)

  • Fecal Short-chain fatty acids

    3 months

  • 16s rRNA

    3 months

Study Arms (3)

Biscuits includes maltodextrin

ACTIVE COMPARATOR

Maltodextrin is a generally recognized as safe (GRAS) food additive. Functional maltodextrin biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g maltodextrin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.

Dietary Supplement: Biscuits maltodextrin

Biscuits includes prebiotics tartoufa inulin

EXPERIMENTAL

Prebiotics is the term for a dietary approach that tries to precisely control the composition and operation of the gut microbiota to promote health. Functional prebiotics biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g tartoufa inulin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.

Dietary Supplement: Biscuits includes prebiotics tartoufa inulin

Biscuits includes prebiotics chicory inulin

EXPERIMENTAL

Prebiotics is the term for a dietary approach that tries to precisely control the composition and operation of the gut microbiota to promote health. Functional prebiotics biscuits were prepared by stacking the biscuits on the table, followed by dispensing of 2g chicory inulin. The biscuits were covered with another piece of biscuit and 1 g of honey was used as binder. The biscuits were packed in bags under vacuum and kept at 40C for the daily supply to the participants.

Dietary Supplement: Biscuits includes prebiotics chicory inulin

Interventions

Biscuits maltodextrinDIETARY_SUPPLEMENT

Biscuits includes maltodextrin

Biscuits includes maltodextrin

Biscuits prebiotics

Biscuits includes prebiotics tartoufa inulin

Biscuits prebiotics

Biscuits includes prebiotics chicory inulin

Eligibility Criteria

Age3 Years - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may not qualify if:

  • gastrointestinal diseases
  • chronic diseases (such as type 1 diabetes)
  • intake of antibiotics within the previous 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mosab Gad

Dokki, Giza Governorate, 12622, Egypt

RECRUITING

Related Publications (3)

  • Gad M, Elbahnasawy AS, Ramadan AA, Yamamah GAN, Hussein L. Dietary intervention with edible film-coated multistrain probiotic Lacticaseibacilli in nondairy food matrices significantly increased the recovery of fecal viable Lacticaseibacilli and improved the performance of several colonic biomarkers among slightly malnourished preschool children. Food Funct. 2024 Jan 22;15(2):977-991. doi: 10.1039/d3fo02829a.

    PMID: 38179614BACKGROUND
  • Mohammad MA, Molloy A, Scott J, Hussein L. Plasma cobalamin and folate and their metabolic markers methylmalonic acid and total homocysteine among Egyptian children before and after nutritional supplementation with the probiotic bacteria Lactobacillus acidophilus in yoghurt matrix. Int J Food Sci Nutr. 2006 Nov-Dec;57(7-8):470-80. doi: 10.1080/09637480600968735.

    PMID: 17162326BACKGROUND
  • Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejia JL, Hansen LH, Leigh Gibson E, Nielsen DS, Costabile A. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 2018 Aug 2;6(1):133. doi: 10.1186/s40168-018-0523-3.

    PMID: 30071894BACKGROUND

MeSH Terms

Conditions

Communicable DiseasesDiarrheaIrritable Bowel Syndrome

Condition Hierarchy (Ancestors)

InfectionsDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms, DigestiveSigns and SymptomsColonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System Diseases

Study Officials

  • Mosab Gad, PhD

    National Research Centre, Egypt

    STUDY CHAIR
  • Amr Elbahnasawy, PhD

    National Research Centre, Egypt

    STUDY CHAIR
  • Sahar Abdelaziz, PhD

    National Research Centre, Egypt

    STUDY CHAIR
  • Laila Hussein, PhD

    National Research Centre, Egypt

    PRINCIPAL INVESTIGATOR
  • Oleg Paliy, PhD

    Wright State University, USA

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Masking Details
Randomized blind parallel three -arm randomized controlled trial (RCT). The RCT is double-blind, in which both the nutritionist and the volunteers are blinded to the actual biscuit allocated to the volunteer; i.e., neither the nutritionist in charge of distributing the biscuit nor the volunteer knows whether the volunteer has received prebiotic rich biscuit or placebo.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2024

First Posted

August 20, 2024

Study Start

June 1, 2023

Primary Completion

February 1, 2025

Study Completion

March 1, 2025

Last Updated

August 20, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will share

The data will be shared after publications

Time Frame
The data will be shared after publications
Access Criteria
Open data access

Locations